Why XOMA (XOMA) Stock Is Surging Today

NEW YORK (TheStreet) -- XOMA Corporation (XOMA) shares are up 18.85% to $4.54 on Tuesday after being upgraded to "buy" from "hold" by analysts at MLV & Co.

The upgrade follows the company's announcement that it was finalizing plans for its gevokizumab Phase 3 program.

Must Read: Warren Buffett's 10 Favorite Growth Stocks 

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. 

The program was finalized following a meeting with regulators from the FDA.

"Our call is based on valuation and optimism around positive upcoming data from the P3 trial for lead asset gevokizumab (gevo) expected sometime mid-year. On positive data, we're expecting ~15-20% of upside to the stock, with potential for additional upside in the form of two other P3 readouts for gevo expected by year-end," MLV said.

The firm maintained its $7 price target on the shares.

XOMA Chart

XOMA data by YCharts

STOCKS TO BUY: TheStreet's Stocks Under $10 has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

More from Markets

Stocks Showing Volatility Heading Into Close

Stocks Showing Volatility Heading Into Close

Intermediate Trade: Disney

Intermediate Trade: Disney

Join Jim Cramer's Club During Our '12 Days of Holiday Deals' Sale and Save 66%!

Join Jim Cramer's Club During Our '12 Days of Holiday Deals' Sale and Save 66%!

It's Another Disappointing Day of Action...So Far

It's Another Disappointing Day of Action...So Far

General Electric Can Be 'Taken Off the Critical List,' Says Jim Cramer

General Electric Can Be 'Taken Off the Critical List,' Says Jim Cramer